Literature DB >> 23671370

Penile tuberculosis following intravesical Bacille Calmette-Guérin immunotherapy.

Anadi Roy Chowdhury1, Ranjan Kumar Dey.   

Abstract

Bacille Calmette-Guérin (BCG) is an effective treatment for patients with superficial bladder cancer and bladder carcinoma in situ (CIS). It may cause side effects usually due to local and systemic inflammatory effects. We report a case of a male patient with non-invasive urothelial carcinoma of urinary bladder (Stage T1) who developed caseating granulomas on his glans penis as a complication of intravesical BCG immunotherapy. Though there are other reported cases of BCG dissemination noted in the literature, penile granuloma is rare. The first reported case was published in 1992 and since then only eleven cases are reported. It appears that both direct infectious processes and hypersensitivity reactions contribute to the clinical manifestations of a systemic BCG infection. Our case possibly represents a local infection of M bovis involving the glans penis.

Entities:  

Keywords:  BCG immunotherapy; penile trauma; penile tuberculosis; urothelial carcinoma

Year:  2013        PMID: 23671370      PMCID: PMC3649605          DOI: 10.4103/0970-1591.109989

Source DB:  PubMed          Journal:  Indian J Urol        ISSN: 0970-1591


  8 in total

Review 1.  BCG intravesical instillations: recommendations for side-effects management.

Authors:  P Rischmann; F Desgrandchamps; B Malavaud; D K Chopin
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

2.  Caseating granulomas on the glans penis as a complication of bacille calmette-guérin intravesical therapy.

Authors:  C G French; L Hickey; D G Bell
Journal:  Rev Urol       Date:  2001

3.  Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy.

Authors:  Hattori Yusuke; Hara Yoshinori; Matsuura Kenichi; Hasegawa Akio
Journal:  Int J Urol       Date:  2006-10       Impact factor: 3.369

4.  Primary tuberculosis of glans penis after intravesical Bacillus Calmette Guerin immunotherapy.

Authors:  V K Sharma; P K Sethy; P N Dogra; Urvashi Singh; P Das
Journal:  Indian J Dermatol Venereol Leprol       Date:  2011 Jan-Feb       Impact factor: 2.545

Review 5.  Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use.

Authors:  Rima Abu-Nader; Christine L Terrell
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

6.  Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy.

Authors:  Faraz Kureshi; Amer N Kalaaji; Larry Halvorson; Mark R Pittelkow; Mark D P Davis
Journal:  J Am Acad Dermatol       Date:  2006-08       Impact factor: 11.527

7.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 8.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta
Journal:  Eur Urol       Date:  2008-04-30       Impact factor: 20.096

  8 in total
  2 in total

Review 1.  Diseases masking and delaying the diagnosis of urogenital tuberculosis.

Authors:  Ekaterina Kulchavenya; Denis Kholtobin
Journal:  Ther Adv Urol       Date:  2015-12

Review 2.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.